1. Home
  2. KPTI vs KOPN Comparison

KPTI vs KOPN Comparison

Compare KPTI & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$7.16

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$2.51

Market Cap

424.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPTI
KOPN
Founded
2008
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
94.6M
424.9M
IPO Year
2013
1992

Fundamental Metrics

Financial Performance
Metric
KPTI
KOPN
Price
$7.16
$2.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$22.17
$4.25
AVG Volume (30 Days)
260.1K
3.2M
Earning Date
02-18-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$142,530,000.00
$45,602,295.00
Revenue This Year
$3.82
N/A
Revenue Next Year
N/A
$43.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.02
52 Week Low
$3.51
$0.71
52 Week High
$12.45
$4.16

Technical Indicators

Market Signals
Indicator
KPTI
KOPN
Relative Strength Index (RSI) 60.42 50.24
Support Level $7.12 $2.28
Resistance Level $7.52 $2.44
Average True Range (ATR) 0.48 0.16
MACD 0.04 0.01
Stochastic Oscillator 71.35 41.96

Price Performance

Historical Comparison
KPTI
KOPN

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: